Abbott (NYSE: ABT) and the Big Ten Conference are relaunching their “We Give Blood” campaign as the United States grapples with a severe national blood shortage. The American Red Cross has declared
More
TrumpRx has spent six months promoting lower drug prices, but critics argue the harder problem is whether patients can actually reach the pharmacy counter. Adam Colborn, vice president of government affairs at
More
Chicago has joined a growing number of cities pushing back against the rapid expansion of data centres, with Mayor Brandon Johnson signing a sweeping executive order on August 11, 2026. The order,
More
The Association of American Law Schools has launched a major new body to scrutinise the regulation and quality of legal education across the United States. The National Task Force on the Regulation
More
Texas Attorney General Ken Paxton faced an uncomfortable moment during a tele-town hall this week, held as part of his ongoing Senate campaign. A caller cut straight to the point, skipping any
More
The FTSE 100 is expected to open 23 points higher on Thursday, following a broad advance across Asian markets overnight. Investor confidence received a boost after US inflation data showed prices slowing
More
Lettuce prices suffered their steepest monthly fall on record in July as a multistate cyclospora outbreak pushed diners to avoid the leafy green entirely. Prices for the vegetable dropped 16.4% from June,
More
Last year, former Manchester United midfielder Paul Pogba made an unexpected investment into Al Haboob, a camel racing club based in Saudi Arabia. The club is the brainchild of two Saudi entrepreneurs,
More
Eli Lilly (LLY) delivered another extraordinary quarter of growth, posting a 48% year-over-year sales increase despite a slower-than-expected launch for its oral obesity drug Foundayo. Lilly reported Foundayo sales of $98 million
More
The strategies that guided bio/pharma commercialization for decades are being overhauled simultaneously, driven by sweeping changes across pricing, technology, and patient care. A fragmenting pricing environment, next-generation therapies straining existing infrastructure, and
More